deprenyl may be useful in the treatment of cocaine dependence

Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria

Bartzokis G, Beckson M, Newton T, Mandelkern M,
Mintz J, Foster JA, Ling W, Bridge TP

Psychiatry Service,
Little Rock VA Medical Center,
AR 72114, USA.
Neuropsychopharmacology 1999 Jun; 20(6):582-90

ABSTRACT

To test the effect of selegiline, a specific monoamine oxidase B (MAO-B) inhibitor, on the cerebral metabolic and euphorigenic effects of cocaine in experienced users, eight cocaine-dependent (CD) subjects were evaluated using a within-subjects design. Each subject participated in two pairs of [F-18]-fluorodeoxyglucose (FDG)-positron emission tomography (PET) scans (baseline scan followed 24 h later by a second scan obtained in conjunction with a 40-mg cocaine infusion) performed before and after a 1-week period of daily treatment with 10 mg selegiline administered orally. The hippocampus and amygdala were evaluated because of their hypothesized involvement in the addiction process, and the thalamus was evaluated as a comparison region. Following 7 days of selegiline treatment, the magnitude of the subjective euphoria ("high") produced by cocaine infusion was reduced by 40% (cocaine by selegiline interaction F = 7.15, df = 1.21, p = .014). Selegiline treatment also altered glucose utilization (normalized against whole brain counts) in the two limbic regions, but not the thalamus. In the amygdala, the effects of cocaine differed, depending upon whether or not patients were being treated with selegiline (cocaine by selegiline interaction F = 4.67, df = 1,19.8, p = .043). A different effect was observed in the hippocampus, where selegiline treatment decreased metabolic activity irrespective of whether cocaine was given (main effect F = 7.70, df = 1.20, p = .012). The concomitant changes in both the subjective experience of the "high" and normalized amygdala glucose utilization after selegiline treatment, suggest that a relationship exists between cocaine-induced euphoria and limbic metabolism. The data suggest that selegiline may be a useful adjunct in the treatment of cocaine dependence.

Deprenyl improves depression

Deprenyl is an effective antidepressant

Deprenyl in treatment-resistant older depressive patients

Deprenyl + phenylalanine was beneficial in 90% of depression patients

Deprenyl   antidepressant effects are by means other than MAO-B inhibition
Deprenyl   treated rats were much more sexually active
Deprenyl   enhances sexual performance and longevity in rats
Deprenyl   may delay the deterioration of neurons during aging
Deprenyl the history of deprenyl
Deprenyl decreases susceptibility to Parkinson's & Alzheimer's disease
Deprenyl restores IGF-1 to youthful levels
Deprenyl protects the vascular endothelium from beta amyloid plaque
Deprenyl reduces cocaine "high"
Deprenyl prolongs animal lifespan by reducing oxidative damage to the brain
Deprenyl may be useful in the treatment of cocaine dependence
Deprenyl increases the life span in Fischer rats
Deprenyl effects on short term memory in young and aged dogs
Deprenyl maintains sexual acitivity in old rats
Deprenyl and Fluoxetine (Prozac) do not interact in combination
Deprenyl prolongs life in elderly dogs
Deprenyl has a cardiac neuroprotective effect
Deprenyl reduces oxidative stress and increases free radical elimination

Deprenyl responses of forebrain neurons to deprenyl

Deprenyl Parkinson's and Alzheimer's patients need 10 mg of deprenyl daily

Deprenyl inhibits tumor growth in rats with mammary tumors

Deprenyl slows the decline of sexual and learning performances in rats

Deprenyl is ten times stronger than methamphetamine as a catecholaminergic

Deprenyl shows favorable results in Tourette's syndrome and narcolepsy

Deprenyl treated rats lived beyond the known maximum lifespan

Deprenyl protects cells from the DNA damage

Deprenyl may protect neurons from ischemic or oxidative damage

Deprenyl prolongs animal lifespan by reducing oxidative damage to the brain

Deprenyl effects on cocaine-induced euphoria

Deprenyl effects on response to experimental cocaine administration

Deprenyl Are metabolites of deprenyl useful or harmful?

Deprenyl slows the progression of Parkinson's disease

Deprenyl suppresses excitotoxic damage in Parkinson's disease

Deprenyl effect of deprenyl on arm movement in early Parkinson's

Deprenyl effect on cognitive functions in early Parkinson's

Deprenyl prolongs the life span of Parkinsonian patients significantly

Deprenyl depression in Parkinson's disease

Deprenyl increases the dopamine content of the nerve terminals in Parkinson's

Deprenyl improves visuo-motor control in early Parkinsonism

Deprenyl management of early Parkinson's disease

Deprenyl delays the onset of disability in Parkinsonian patients

Deprenyl and tocopherol antioxidative therapy of Parkinsonism

Deprenyl slows the death of nigral neurons in Parkinson's disease

Deprenyl + levodopa treated Parkinson's patients live longer

Deprenyl stimulates biosynthesis of cytokines interleukin-1 & 6

Deprenyl effect of MAO-B inhibitors on MPP+ toxicity

Deprenyl modulates the activity of catecholamine-sensitive neurons

Deprenyl improves the performance of patients with Alzheimer's disease

Deprenyl for Alzheimer's disease

Deprenyl MAO-B inhibitors in the treatment of Alzheimer's disease

Deprenyl in the treatment of Alzheimer's disease

Deprenyl stimulates biosynthesis of cytokines interleukin-1 & 6

Deprenyl and age-related decline of the striatal dopaminergic system

Deprenyl increases dopamine in the striatum of primates

Deprenyl use in treatment-resistant elderly depression patients

Deprenyl protects against neurotoxins

Deprenyl   increased rat lifespan by 5%
Deprenyl   neuroprotective action
Deprenyl   inhibition of human LDL oxidation
Deprenyl   facilitates recovery after stroke

Deprenyl effects during smoking and short-term abstinence

Hit Counter